Diabetes and everolimus-eluting stents: What we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial

Chiara Bernelli, Georgina Fuertes Ferre, Alaide Chieffo

Research output: Contribution to journalArticle


Evaluation of: Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585-1591 (2012). Percutaneous coronary interventions in diabetic patients are still challenging in the drug-eluting stents era because of the more extensive coronary artery disease and the presence of comorbidities. New-generation drug-eluting stents have demonstrated an improved efficacy and safety in patients treated with percutaneous coronary interventions. The SORT OUT IV substudy has investigated the clinical impact of the everolimus-eluting stents versus sirolimus-eluting stents in both the diabetic and nondiabetic population.

Original languageEnglish
Pages (from-to)151-154
Number of pages4
JournalExpert Review of Cardiovascular Therapy
Issue number2
Publication statusPublished - Feb 2013



  • diabetes mellitus
  • drug-eluting stents
  • major adverse cardiac events
  • percutaneous coronary intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this